WUXIBIOLOGICSINVESTMENTSLIMITED目前是14家企业直接控股股东,包括无锡药明企业管理有限公司、控股比例达100%,上海药明检测有限公司、控股比例达100%等;WUXIBIOLOGICSINVESTMENTSLIMITED间接持股企业23家,包括投资无锡元康投资管理有限公司、投资占比达100%,无锡药明生物技术股份有限公司、投资占比达100%等;目前WUXIBIOLOGICS...
WUXIBIOLOGICSINVESTMENTSLIMITED目前是14家企业直接控股股东,包括无锡药明生物技术股份有限公司、控股比例达100%,无锡雅康实业投资有限公司、控股比例达100%等;WUXIBIOLOGICSINVESTMENTSLIMITED间接持股企业22家,包括投资无锡药明生物技术股份有限公司、投资占比达100%,河北药明生物技术有限公司、投资占比达100%等;目前WUXI...
简介:药明生物投资有限公司(WuXi Biologics Investments Limited) 评分- 法定代表人 - 注册资本 - 成立日期 - - - - -天眼风险 自身风险0 暂无自身风险 周边风险0 暂无周边风险 历史风险0 暂无历史风险 预警提醒0 暂无预警提醒基本信息 法定代表人 - 成立日期 - 经营状态 - 注册资本 - 实缴资本 - 统一社会...
Ltd. Since January 2014, he has been serving as a director and general manager of Temasek Holdings Advisors (Beijing) Co., Ltd. Dr. Wu has concurrently been serving as a non-executive director of WuXi Biologics (Cayman) Inc. (stock code: 2269.HK). Dr. Wu obtained a bachelor's degree...
Bull or Bear, Seeking Alpha is there Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. Create Free Account WXIBFWuXi Biologics (Cayman) Inc. Related Analysis 391 followers $2.190.02 (+0.92%)12:22 PM 01/10/25 ...
Third-quarter 2009 GAAP net income grew 97% year over year due to the 72% increase in net income from continuing operations and lower losses from discontinued operations. Third-quarter 2008 GAAP net income included a loss from discontinued operations of $1.2 million related to the biologics manuf...
"We are pleased to join the Consortium to acquire Ambrx, a top-tier innovative biologics company with a cutting-edge second-generation ADC technology platform," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC...
CDMO/CMO services and clinical research and other CRO services. In addition to investments in our operations, i.e. new talent, new laboratories and facilities, our unique ecosystem that we are relentlessly building provided additional opportunities for us to effectively put our capital to use l...
"This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC platform and biologics development capabilities to better serve our global customers." "We are excited to advance Ambrx's development programs and technol...
Dr. Yibing Wu has the following work experience: • Since May 2016, he has been serving as a non-executive Director of WuXi Biologics, a company listed on the Main Board of the Stock Exchange (stock code: 2269) and has been responsible for providing guidance on corporate strategy and ...